{"id":"NCT02320149","sponsor":"Almirall, S.A.","briefTitle":"Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne","officialTitle":"A Randomized, Multicenter, Double-blind, Placebocontrolled Study to Evaluate the Efficacy and Safety of 1.5 mg/kg Per Day of Sarecycline Compared to Placebo in the Treatment of Acne Vulgaris","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-12-18","primaryCompletion":"2017-02-01","completion":"2017-02-01","firstPosted":"2014-12-19","resultsPosted":"2018-05-17","lastUpdate":"2019-02-15"},"enrollment":968,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Acne Vulgaris"],"interventions":[{"type":"DRUG","name":"Sarecycline","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Sarecycline","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"To evaluate the efficacy and safety of an approximate 1.5mg/kg/day dose of oral sarecycline compared to placebo in the treatment of moderate to severe facial acne vulgaris","primaryOutcome":{"measure":"Absolute Change in Facial Inflammatory Lesion Counts at Week 12","timeFrame":"Baseline (Day 1) to Week 12","effectByArm":[{"arm":"Sarecycline","deltaMin":-15.3,"sd":0.6},{"arm":"Placebo","deltaMin":-10.1,"sd":0.6}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.0001"}]},"eligibility":{"minAge":"9 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":11,"exclusionCount":20},"locations":{"siteCount":57,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":481},"commonTop":[]}}